DAYANG BIOTECH(SZ:003017) Xin Lang Cai Jing·2025-09-15 05:43Group 1 - The core point of the news is the performance and financial details of Zhejiang Dayang Biological Technology Group Co., Ltd, which saw a stock price increase of 5.02% to 35.15 CNY per share, with a total market capitalization of 2.953 billion CNY [1] - The company was established on January 1, 1976, and went public on October 26, 2020, focusing on the production and sales of chemical raw materials, including inorganic salts and veterinary raw materials [1] - The revenue composition of the company is as follows: 69.91% from inorganic salt products, 18.35% from veterinary raw materials, 7.46% from fluorine-containing chemicals, and 4.28% from other products [1] Group 2 - From the perspective of fund holdings, one fund under Huaxia Fund has a significant position in Dayang Biological, specifically the Huaxia Steady Growth One-Year Holding Mixed A fund, which held 2,400 shares, accounting for 0.14% of the fund's net value [2] - The Huaxia Steady Growth One-Year Holding Mixed A fund was established on August 11, 2023, with a latest scale of 29.2614 million CNY, and has achieved a year-to-date return of 1.93% [2] - The fund manager, Song Yang, has been in the position for 8 years and 304 days, with the fund's total asset scale at 9.393 billion CNY, achieving a best return of 76.17% and a worst return of -13.01% during his tenure [2]